Key facts
- FDA advisers are reviewing seven popular peptides for safety and effectiveness.
- Consumer demand for peptides is growing, with testimonials on social media.
- FDA scientists have raised concerns about the lack of clinical data and potential risks.
- Some members of the advisory panel have financial ties to the peptide industry.
- The panel's votes are not binding, and the FDA can override recommendations.
The U.S. Food and Drug Administration's advisory panel is convening for a two-day meeting to review seven popular peptides, substances that have gained traction as a wellness trend despite limited evidence of their safety and effectiveness. Health Secretary Robert F. Kennedy Jr. has expressed support for peptides and aims to ease restrictions.
FDA career scientists have voiced concerns regarding the insufficient data to support wider availability of these compounds, particularly from compounding pharmacies. Many medical and scientific experts share these reservations, highlighting the lack of human studies and potential risks such as contamination and allergic reactions.
Despite the scientific skepticism, the panel includes individuals with financial ties to the peptide industry, such as owners of wellness clinics and online businesses that promote these substances. The FDA has added external experts without industry connections to the panel to address conflict of interest concerns.
Supporters, including the American Academy of Peptide Medicine, argue that peptides help many people and that regulated pharmacies should offer them legally. They have submitted over 1,900 public comments to the FDA. The panel's votes on whether to allow the peptides for compounding are non-binding, and the FDA ultimately makes the final decision.
Industry watchers suggest a likely outcome could be a temporary policy that reassures pharmacies against enforcement actions for compounding these peptides, as formal regulatory changes can be lengthy.